Different antibody responses between liver and kidney transplant recipients elicited by third doses of COVID-19 mRNA vaccines-Reference-Cited by-同舟云学术

Different antibody responses between liver and kidney transplant recipients elicited by third doses of COVID-19 mRNA vaccines

Published:2023-02-21 Issue:1 Volume:37 Page:49-56
ISSN:2671-8790
Container-title:Korean Journal of Transplantation
language:en
Short-container-title:Korean J Transplant

Author:

Lim So Yun¹^ORCID,Yoon Young-In²^ORCID,Kim Ji Yeun¹^ORCID,Tak Eunyoung³^ORCID,Kwon Hyunwook⁴^ORCID,Shin Sung⁴^ORCID,Kim Young Hoon⁴^ORCID,Song Gi-Won²^ORCID,Kim Sung-Han¹^ORCID,Lee Sung-Gyu²^ORCID

Affiliation:

1. Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

2. Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

3. Department of Convergence Medicine, Asan Medical Institute of Convergence Science and Technology (AMIST), Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

4. Division of Kidney and Pancreas Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Funder

Korea Health Industry Development Institute

National Institute of Infectious Diseases

National Institute of Health

Publisher

The Korean Society for Transplantation

Subject

Transplantation,Immunology

Link

http://pdf.medrang.co.kr/JKST/2023/037/kjt-37-1-49.pdf

Reference17 articles.

1. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

2. Effectiveness of first, second, and third COVID-19 vaccine doses in solid organ transplant recipients: A population-based cohort study from Canada

3. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study

4. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

5. Centers for Disease Control and Prevention (CDC). COVID-19 vaccines for people who are moderately or severely immunocompromised [Internet]. CDC; 2022 [cited 2022 Aug 17]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html.